Development of an Allele-specific PCR for Detection of the K65R Resistance Mutation in Patients Infected with Subtype C Human Immunodeficiency Virus Type 1

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2009 Dec 10

PMID 19995921

Citations 8

Authors

Thomas A Toni

Bluma G Brenner

Eugene L Asahchop

Michel Ntemgwa

Daniella Moisi

Mark A Wainberg

Affiliations

Soon will be listed here.

Abstract

The selection of drug-resistant variants of human immunodeficiency virus type 1 (HIV-1) is an impediment to the efficiency of antiretroviral (ARV) therapy. We have developed an allele-specific real-time PCR assay to explore the presence of K65R minority species among treated HIV-1 subtype B and C infections. Thirty HIV-1 subtype C- and 26 subtype B-infected patients lacking K65R as determined by conventional sequencing methods were studied, and viral minority species were found in four HIV-1 subtype C samples.

Citing Articles

Patterns of human immunodeficiency virus drug resistance mutations in people living with human immunodeficiency virus in India: A scoping review.

Balaji S, Madhumathi J, Bhargava A, Singh T, Mahajan N, Ambalkar D Indian J Sex Transm Dis AIDS. 2022; 43(1):13-19.

PMID: 35846552 PMC: 9282713. DOI: 10.4103/ijstd.ijstd_2_21.

Evaluation of the expression levels of BRAF mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay.

Tran T, Dang K, Pham Q, Nguyen U, Trinh N, Hoang L BMC Cancer. 2020; 20(1):368.

PMID: 32357861 PMC: 7195771. DOI: 10.1186/s12885-020-06862-w.

Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.

Tang Y, Ou C Emerg Microbes Infect. 2015; 1(8):e19.

PMID: 26038427 PMC: 3630918. DOI: 10.1038/emi.2012.15.

Extendable blocking probe in reverse transcription for analysis of RNA variants with superior selectivity.

Ho T, Dang K, Lintula S, Hotakainen K, Feng L, Olkkonen V Nucleic Acids Res. 2014; 43(1):e4.

PMID: 25378315 PMC: 4288146. DOI: 10.1093/nar/gku1048.

Low-abundance resistant mutations in HIV-1 subtype C antiretroviral therapy-naive individuals as revealed by pyrosequencing.

Gonzalez S, Tully D, Gondwe C, Wood C Curr HIV Res. 2013; 11(1):43-49.

PMID: 23305169 PMC: 4005869.

References

Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L . HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008; 24(11):1449-54. PMC: 8884175. DOI: 10.1089/aid.2008.0180. View

White K, Margot N, Ly J, Chen J, Ray A, Pavelko M . A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS. 2005; 19(16):1751-60. DOI: 10.1097/01.aids.0000189851.21441.f1. View

Hosseinipour M, van Oosterhout J, Weigel R, Phiri S, Kamwendo D, Parkin N . The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009; 23(9):1127-34. PMC: 2896488. DOI: 10.1097/QAD.0b013e32832ac34e. View

Diallo K, Marchand B, Wei X, Cellai L, Gotte M, Wainberg M . Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity. J Virol. 2003; 77(16):8621-32. PMC: 167213. DOI: 10.1128/jvi.77.16.8621-8632.2003. View

Parikh U, Zelina S, Sluis-Cremer N, Mellors J . Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS. 2007; 21(11):1405-14. DOI: 10.1097/QAD.0b013e3281ac229b. View

Gottlieb G, Badiane N, Hawes S, Fortes L, Toure M, Ndour C . Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa. Clin Infect Dis. 2009; 48(4):476-83. PMC: 3671065. DOI: 10.1086/596504. View

Coutsinos D, Invernizzi C, Xu H, Moisi D, Oliveira M, Brenner B . Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol. 2008; 83(4):2029-33. PMC: 2643749. DOI: 10.1128/JVI.01349-08. View

Parikh U, Barnas D, Faruki H, Mellors J . Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J Infect Dis. 2006; 194(5):651-60. DOI: 10.1086/505711. View

Johnson J, Li J, Wei X, Lipscomb J, Irlbeck D, Craig C . Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med. 2008; 5(7):e158. PMC: 2488194. DOI: 10.1371/journal.pmed.0050158. View

10.

Johnson V, Brun-Vezinet F, Clotet B, Gunthard H, Kuritzkes D, Pillay D . Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007; 15(4):119-25. View

11.

Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S . High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother. 2006; 50(12):4182-5. PMC: 1693987. DOI: 10.1128/AAC.00714-06. View

12.

Invernizzi C, Coutsinos D, Oliveira M, Moisi D, Brenner B, Wainberg M . Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis. 2009; 200(8):1202-6. DOI: 10.1086/605894. View

13.

Thomson M, Najera R . Molecular epidemiology of HIV-1 variants in the global AIDS pandemic: an update. AIDS Rev. 2006; 7(4):210-24. View

14.

Frankel F, Marchand B, Turner D, Gotte M, Wainberg M . Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 2005; 49(7):2657-64. PMC: 1168713. DOI: 10.1128/AAC.49.7.2657-2664.2005. View

15.

Svarovskaia E, Margot N, Bae A, Waters J, Goodman D, Zhong L . Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J Acquir Immune Defic Syndr. 2007; 46(2):174-80. DOI: 10.1097/QAI.0b013e31814258c0. View

16.

Delaunay C, Brun-Vezinet F, Landman R, Collin G, Peytavin G, Trylesinski A . Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J Virol. 2005; 79(15):9572-8. PMC: 1181609. DOI: 10.1128/JVI.79.15.9572-9578.2005. View

17.

Grant R, Wainberg M . Chemoprophylaxis of HIV infection: moving forward with caution. J Infect Dis. 2006; 194(7):874-6. DOI: 10.1086/507314. View

18.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W . Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J Clin Virol. 2008; 41(4):310-3. DOI: 10.1016/j.jcv.2007.12.015. View

19.

Margot N, Waters J, Miller M . In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother. 2006; 50(12):4087-95. PMC: 1693985. DOI: 10.1128/AAC.00816-06. View

20.

Toni T, Asahchop E, Moisi D, Ntemgwa M, Oliveira M, Masquelier B . Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother. 2009; 53(4):1670-2. PMC: 2663097. DOI: 10.1128/AAC.01494-08. View